In vivo studies under sorafenib treatment, MM cells were able to undergo autophagy, and observed a downregulation of Mcl-1, suggesting that the co-targeting of Mcl-1 by sorafenib and of Bcl-2/Bcl-xL by the ABT-737 improves the efficacy of sorafenib in MM [152]. This evidence concerns the gene BCL2 and Miyoshi myopathy.